Production of the lantibiotic cinnamycin with genes isolated from streptomyces cinnamoneus
CA 2446010 A1 · Owner: Bibb, Mervyn James · Inventors: Widdick, David Andrew; Bibb, Mervyn James
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A 17kb nucleic acid fragment, which confers production of the lantibiotic cinnamycin on non-producer Streptomycete strains has been isolated from , Streptomyces cinnamoneus cinnamoneus DSM 40005 and characterised. Also provided are variants of the 17kb fragment including variants in which nonessential genes are deleted and variants in which the propeptide sequence of the cinnamycin structural gene is altered for example replaced with the , propeptide sequence of similar B-type lantibiotics. Also provided are vectors host cells and methods of lantibiotic production using the nucleic acid of the invention, and libraries of variants.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 29, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 29, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 29, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.